NKTX MEXC RealStocks
Own real NKTX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 15:15:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Nkarta, Inc. (NKTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.17, with a market capitalization of $90.61M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.13 to $3.72. This page covers its latest market performance, valuation, price trends and company information.
$90.61M | |
$1.28 | |
$1.30 | |
$1.17 | |
$1.26 | |
179.90K | |
975.92K | |
-- | |
$3.72 | |
$1.13 | |
-- | |
-- |
Nkarta, Inc. (NKTX) is currently trading at $1.17 as of 2026-11-13 14:58:49, down 4.35% ($0.05) from the previous close of $1.27
During today's regular trading session, NKTX has traded between $1.17 and $1.30, with a trading volume of 179.90K shares. The current price is near the lower end of today's range.
Over the past seven days, Nkarta, Inc. (NKTX) moved from $1.73 to $1.17, representing a decline of 32.66% ($0.57).
The stock traded between $1.13 and $1.84 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.54 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.4%
NKTX is currently trading at $1.17, placing it 1.4% of the way from its 52-week low of $1.13 to its 52-week high of $3.72. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 103 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Nkarta, Inc. (NKTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to NKTX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between NKTX shares and USD.
NKTX Shares to USD
1.00 NKTX shares = 1.165 USD
Calculations are estimates based on the latest available price and are for reference only.